Arcutis Biotherapeutics, Inc. splits its revenue into 4 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was ZORYVE Foam at $75.1 million, 52% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
507
|
144
|
130
|
105
|
128
|
99
|
82
|
64
|
69
|
| ZORYVE Foam |
—
|
75
+50.9%
share 52.2%
|
67
+71.8%
share 51.9%
|
50
+64.1%
share 47.1%
|
63
+101.3%
share 49.1%
|
50
share 50.2%
|
39
share 48.1%
|
30
share 47.4%
|
31
share 44.9%
|
| ZORYVE Cream0.3 |
—
|
38
+23.9%
share 26.2%
|
35
+27.6%
share 27.2%
|
33
+39.7%
share 31.0%
|
39
+28.2%
share 30.9%
|
30
share 30.7%
|
28
share 34.0%
|
23
share 36.6%
|
31
share 44.3%
|
| ZORYVE Cream0.15 |
—
|
27
+43.9%
share 18.9%
|
24
+65.8%
share 18.7%
|
22
+112.8%
share 20.6%
|
24
+227.9%
share 19.2%
|
19
share 19.1%
|
15
share 17.9%
|
10
share 16.0%
|
7
share 10.8%
|
| ZORYVE Cream0.05 |
—
|
4
share 2.6%
|
3
share 2.3%
|
1
share 1.3%
|
—
|
—
|
—
|
—
|
—
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ARQT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Westlake Village, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1787306
- Former names
- Arcutis, Inc. (until Sep 9, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.